异丙托溴铵、布地奈德联合用药对急性哮喘患者血清IL-25、IL-17水平的影响观察
|
摘要
目的观察异丙托溴铵、布地奈德联合用药对急性哮喘患者血清IL-25、 IL-17水平的影响。方法按照入院顺序将60例急性哮喘患者随机分为实验组(采用异丙托溴铵联合布地奈德治疗)和对照组(单纯采用布地奈德治疗)各30例,两组均予以抗感染、止咳化痰、吸氧等常规治疗。比较两组患者的临床疗效,治疗前及治疗7 d后的IL-17、 IL-25水平。结果实验组的治疗总有效率明显高于对照组(P <0.05)。治疗7 d后,两组患者的血清IL-17、 IL-25水平均低于治疗前,且实验组的血清IL-17、 IL-25水平均明显低于对照组(P均<0.05)。结论异丙托溴铵、布地奈德联合用药治疗哮喘急性的疗效确切,可调节机体免疫状态,促进症状缓解。
Objective To observe the influence of ipratropium bromide combined with budesonide on serum IL-25 and IL-17 levels in patients with acute asthma. Methods 60 cases of patients with acute asthma were randomly divided into experimental group(ipratropium bromide combined with budesonide) and control group(only budesonide) according to the admission order, with 30 cases in each group.Both groups were given routine treatment of anti-infection, relieving cough and reducing sputum and oxygen uptake. The clinical efficacy,and the IL-17 and IL-25 levels before treatment and 7 d after treatment of the two groups were compared. Results The total effective rate of treatment in experimental group was significantly higher than that in control group(P <0.05). 7 d after treatment, the serum IL-17 and IL-25 levels of the two groups were lower than those before treatment, and the IL-17 and IL-25 levels of the experimental group were significantly lower than those of the control group(P <0.05). Conclusions Ipratropium bromide combined with budesonide has exact efficacy in the treatment of acute asthma, which can regulate the body immune status and promote symptom relief.
Objective To observe the influence of ipratropium bromide combined with budesonide on serum IL-25 and IL-17 levels in patients with acute asthma. Methods 60 cases of patients with acute asthma were randomly divided into experimental group(ipratropium bromide combined with budesonide) and control group(only budesonide) according to the admission order, with 30 cases in each group.Both groups were given routine treatment of anti-infection, relieving cough and reducing sputum and oxygen uptake. The clinical efficacy,and the IL-17 and IL-25 levels before treatment and 7 d after treatment of the two groups were compared. Results The total effective rate of treatment in experimental group was significantly higher than that in control group(P <0.05). 7 d after treatment, the serum IL-17 and IL-25 levels of the two groups were lower than those before treatment, and the IL-17 and IL-25 levels of the experimental group were significantly lower than those of the control group(P <0.05). Conclusions Ipratropium bromide combined with budesonide has exact efficacy in the treatment of acute asthma, which can regulate the body immune status and promote symptom relief.
引文
[1]田野.布地奈德联合异丙托溴铵雾化吸入治疗支气管哮喘急性发作的临床研究[J].实用临床医药杂志, 2017, 21(11):162-163.
[2]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(2016年版)[J].中华结核和呼吸杂志, 2016, 39(9):675-697.
[3]杨琪炜.沙丁胺醇联合布地奈德雾化吸入治疗支气管哮喘急性发作的疗效观察[J].河北医药, 2013, 35(8):1147-1148.
[4]王鹏程,张晓.布地奈德沙丁胺醇联合异丙托溴铵雾化吸入治疗支气管哮喘急性发作临床效果观察[J].河北医学, 2015, 21(7):1099-1102.
[5]董灵芝,任志艳,董书领.布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗小儿哮喘的疗效及护理[J].实用临床医药杂志, 2015,19(8):97-100.
[6]杜端林,周锐.支气管哮喘急性发作期患者血清IL-17和转化生长因子β2的表达及其意义[J].国际呼吸杂志, 2017, 37(12):881-885.
[2]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(2016年版)[J].中华结核和呼吸杂志, 2016, 39(9):675-697.
[3]杨琪炜.沙丁胺醇联合布地奈德雾化吸入治疗支气管哮喘急性发作的疗效观察[J].河北医药, 2013, 35(8):1147-1148.
[4]王鹏程,张晓.布地奈德沙丁胺醇联合异丙托溴铵雾化吸入治疗支气管哮喘急性发作临床效果观察[J].河北医学, 2015, 21(7):1099-1102.
[5]董灵芝,任志艳,董书领.布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗小儿哮喘的疗效及护理[J].实用临床医药杂志, 2015,19(8):97-100.
[6]杜端林,周锐.支气管哮喘急性发作期患者血清IL-17和转化生长因子β2的表达及其意义[J].国际呼吸杂志, 2017, 37(12):881-885.